期刊文献+

利拉鲁肽对2型糖尿病患者脂代谢的影响 被引量:2

下载PDF
导出
摘要 目的:2型糖尿病患者应用利拉鲁肽治疗,对其脂代谢情况、疾病改善情况进行研究分析。方法:选取2018年1月至2019年1月信宜市人民医院收治的2型糖尿病患者40例,按照随机数字表法分成观察组(n=20)和对照组(n=20),对照组患者采用传统方案应用甘精胰岛素,观察组患者采用利拉鲁肽,比较两组患者的脂代谢各项指标改善情况。结果:两组患者经临床治疗3周后,相比于治疗前,两组患者的糖化血红蛋白(HbAlc)、空腹血糖(FPG)、体质量指数(BMI)、餐后2 h血糖(2h PG)及血脂各项指标均明显更低,差异具有统计学意义(P <0.05);治疗后,两组患者血脂〔总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDC-C)〕指标均明显低于治疗前,差异具有统计学意义(P <0.05);且治疗后观察组患者血脂(TC、TG、LDL–C)指标均明显优于对照组,组间比较,差异均具有统计学意义(P <0.05)。结论:2型糖尿病患者在临床治疗中应用利拉鲁肽效果更明显,能够有效改善患者脂代谢与血脂情况。
作者 陈珊
机构地区 信宜市人民医院
出处 《深圳中西医结合杂志》 2019年第10期176-177,共2页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献8

二级参考文献44

  • 1Malo MS.A high level of intestinal alkaline phosphatase is protective against type 2 diabetes mellitusirrespective of obesity[J].EBioMedicine,2015,2(12):2016-2023.
  • 2Ghane Basiri M,Sotoudeh G,Djalali M,et al.Association of major dietary patterns with general and abdominal obesity in iranian patients withtype 2 diabetes mellitus[J].Int J Vitam Nutr Res,2015,85(3-4):145-155.
  • 3Mikaelyan NP,Terentev AA,Nguen KH,et al.Changes of blood fatty acid in women with obesity and type 2 diabetes mellitus[J].Biomed Khim,2015,61(6):760-764.
  • 4Cotugno M,Nosso G,Saldalamacchia G,et al.Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severeobesity:a 12-month retrospective evaluation[J].Acta Diabetol,2015,52(2):331-336.
  • 5Ando T,Haraguchi A,Matsunaga T,et al.Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity[J].Intern Med,2014,53(16):1791-1795.
  • 6Nagakubo D,Shirai M,Nakamura Y,et al.Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity[J].Comp Med,2014,64(2):121-127.
  • 7Hiramatsu T,Ozeki A,Asai K,et al.Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis[J].Ther Apher Dial,2015,19(6):598-605.
  • 8Guo XH.The value of short-and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus:experience with exenatide[J].Curr Med Res Opin,2016,32(1):61-76.
  • 9Johnston SS,Nguyen H,Cappell K,et al.Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutidein the United States[J].J Med Econ,2015,18(9):666-677.
  • 10Chiefari E,Capula C,Vero A,et al.Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy[J].Diabetes Technol Ther,2015,17(7):468-474.

共引文献117

同被引文献21

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部